JP2005532319A5 - - Google Patents

Download PDF

Info

Publication number
JP2005532319A5
JP2005532319A5 JP2004503481A JP2004503481A JP2005532319A5 JP 2005532319 A5 JP2005532319 A5 JP 2005532319A5 JP 2004503481 A JP2004503481 A JP 2004503481A JP 2004503481 A JP2004503481 A JP 2004503481A JP 2005532319 A5 JP2005532319 A5 JP 2005532319A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
halogen
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004503481A
Other languages
English (en)
Japanese (ja)
Other versions
JP4476802B2 (ja
JP2005532319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2003/000305 external-priority patent/WO2003095467A1/en
Publication of JP2005532319A publication Critical patent/JP2005532319A/ja
Publication of JP2005532319A5 publication Critical patent/JP2005532319A5/ja
Application granted granted Critical
Publication of JP4476802B2 publication Critical patent/JP4476802B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004503481A 2002-05-08 2003-05-08 ロックト核酸誘導体の製造 Expired - Lifetime JP4476802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16
PCT/DK2003/000305 WO2003095467A1 (en) 2002-05-08 2003-05-08 Synthesis of locked nucleic acid derivatives

Publications (3)

Publication Number Publication Date
JP2005532319A JP2005532319A (ja) 2005-10-27
JP2005532319A5 true JP2005532319A5 (cg-RX-API-DMAC7.html) 2006-04-27
JP4476802B2 JP4476802B2 (ja) 2010-06-09

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004503481A Expired - Lifetime JP4476802B2 (ja) 2002-05-08 2003-05-08 ロックト核酸誘導体の製造

Country Status (9)

Country Link
EP (1) EP1501848B1 (cg-RX-API-DMAC7.html)
JP (1) JP4476802B2 (cg-RX-API-DMAC7.html)
AT (1) ATE369375T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222743B2 (cg-RX-API-DMAC7.html)
CA (1) CA2484526C (cg-RX-API-DMAC7.html)
DE (1) DE60315444T2 (cg-RX-API-DMAC7.html)
DK (1) DK1501848T3 (cg-RX-API-DMAC7.html)
ES (1) ES2290448T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003095467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
ES2344566T3 (es) 2003-12-23 2010-08-31 Santaris Pharma A/S Compuestos oligomericos para la modulacion de bcl-2.
EP1824975B9 (en) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
BRPI0515726A8 (pt) 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
EA201100811A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20100062994A1 (en) * 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
EP2183360B1 (en) 2007-08-30 2017-01-11 Hadasit Medical Research Services&Development Company Ltd. Nucleic acid sequences comprising nf-(kappa)b binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー RNAiにおけるオフターゲット表現型の影響を減少させるためのSiRNA配列非依存性修飾フォーマットおよびその安定化型
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CN103842387B (zh) * 2011-07-21 2017-04-26 罗地亚运作公司 瓜耳胶羟丙基三甲基氯化铵及其在发用处理组合物中的用途
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
EP2943570B1 (en) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
MX367083B (es) 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3256586B1 (en) 2015-02-15 2021-04-07 Arcturus Therapeutics, Inc. Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸GuNA,其製造方法,及中間體化合物
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
CN116059236A (zh) 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
US20220354888A1 (en) 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
KR20260009385A (ko) 2017-08-25 2026-01-19 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス,インク. コレステリルエステル蓄積症の処置のための方法及び組成物
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
KR20230170690A (ko) 2021-03-26 2023-12-19 뉴미르나 테라퓨틱스 에이피에스 MicroRNA-134 억제제들
MX2023011101A (es) 2021-03-26 2024-01-10 Neumirna Therapeutics Aps Inhibidores de microrna-27b.
JP2024522272A (ja) 2021-06-04 2024-06-13 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
AU2022329834A1 (en) 2021-08-17 2024-03-07 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
EP4388096A1 (en) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonucleotides targeting adenosine kinase
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
EP4450626A1 (en) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Fnip2 inhibitors for treating ataxia telangiectasia
WO2025015676A1 (zh) * 2023-07-21 2025-01-23 瑞孚医药科技(广州)有限公司 碳环核苷、寡核苷酸及其制备方法和医药用途
EP4512899A1 (en) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4 aso compositions for treatment of atherosclerosis in humans
WO2026068729A1 (en) 2024-09-26 2026-04-02 Neumirna Therapeutics Aps Antimir-27b for treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356824T1 (de) * 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
EP1334109B1 (en) * 2000-10-04 2006-05-10 Santaris Pharma A/S Improved synthesis of purine locked nucleic acid analogues

Similar Documents

Publication Publication Date Title
US6927291B2 (en) Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides
AU636108B2 (en) Therapeutic 6-substituted purine carbocyclic nucleosides and pharmaceutically acceptable derivatives thereof
JP5831455B2 (ja) モルホリノ核酸誘導体
US6831174B2 (en) Processes for preparing substituted 1, 3-oxathiolanes with antiviral properties
CN1285843A (zh) 化合物
US6600044B2 (en) Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
PT90159B (pt) Processo para a preparacao de bis(hidroximetil) ciclobutil purinas e pirimidinas
WO2009091031A1 (ja) アデニン化合物の製造方法
EP0521923B1 (en) Process for producing nucleosides, and analogs therof
EP0369583B1 (en) Chemical process for the preparation of purine derivatives
CN1232466A (zh) 膦酸酯-核苷酸化合物
US8399655B2 (en) Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
JPH02270864A (ja) フルオロカルバサイクリックヌクレオシドおよびその製造法
CN1036712C (zh) 抗病毒剂[1R-(1α,2β,3α)]-2-氨基-9-[2,3-双(羟甲基)环丁基]-1,9-二氢-6H-嘌呤-6-酮的制备方法
JP5690731B2 (ja) 2,4−二置換1,3−オキサチオランヌクレオシドの鏡像異性体分割
EP0479822B1 (en) Therapeutic nucleosides
CN101142211B (zh) 制备光学活性顺式-2-羟甲基-4-(胞嘧啶-1’-基)-1,3-氧硫杂戊环或其药物可接受盐的工艺和方法
BR112014008622B1 (pt) Derivados de ciclopropano, seus métodos de preparação e seu uso
JP4174895B2 (ja) ヌクレオシド誘導体とその製法
JP2002293792A (ja) ヌクレオシド又は糖のフッ素化誘導体の製造方法
CN120957994A (zh) 用于制备寡核苷酸类似物或其盐的中间体及其制备方法
JPH01100190A (ja) ヌクレオシド類
JPH0296589A (ja) ヌクレオシド類
JPH02277A (ja) ヌクレオシド類縁化合物
JPH05194421A (ja) 新規シクロプロパン誘導体